Daiichi Sankyo (OTCMKTS:DSNKY) Stock Price Up 5.2% – Should You Buy?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price shot up 5.2% during mid-day trading on Monday . The company traded as high as $18.43 and last traded at $18.40. 3,199 shares were traded during trading, a decline of 99% from the average daily volume of 343,306 shares. The stock had previously closed at $17.49.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Daiichi Sankyo has a consensus rating of “Reduce”.

Daiichi Sankyo Price Performance

The stock has a market cap of $34.07 billion, a price-to-earnings ratio of 21.27, a price-to-earnings-growth ratio of 2.53 and a beta of -0.11. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92. The company has a 50-day simple moving average of $17.49 and a two-hundred day simple moving average of $17.27.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, equities research analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.